Literature DB >> 22417249

Pulmonary embolism in sickle cell disease: a case-control study.

E M Novelli1, C Huynh, M T Gladwin, C G Moore, M V Ragni.   

Abstract

INTRODUCTION: A pulmonary embolism (PE) is a leading cause of mortality in hospitalized patients, yet the prevalence of PE in sickle cell disease (SCD) and its relation to disease severity or intrinsic hypercoagulability are not established.
METHODS: We estimated inpatient PE incidence and prevalence among SCD and non-SCD populations in Pennsylvania, and compared severity of illness and mortality, using Pennsylvania Health Care Cost Containment Council (PHC4) discharge data, 2001-2006. Risk factors for PE were assessed in a case-control study of discharges from the University of Pittsburgh Medical Archival Records System (MARS).
RESULTS: The incidence of inpatient PE was higher in the SCD PA population than in the non-SCD Pennsylvania population, 2001-2006. The PE prevalence among SCD discharges ≤ 50 years of age, 0.57%, was similar to that in non-SCD Pennsylvania discharges, 0.60%, and unchanged after adjustment for race. Among SCD discharges, those developing PE were significantly older, with a longer length of stay, greater severity of illness and higher mortality, P < 0.001, than SCD without a PE. Among PE discharges, SCD had a similar severity of illness, P = 0.77, and mortality, P = 0.39, but underwent fewer computerized tomographic scans, P = 0.006, than non-SCD with PE. In the local case-control study, no clinical or laboratory feature was associated with PE.
CONCLUSIONS: The incidence of PE is higher and chest computed tomography (CT) utilization is lower in SCD than non-SCD inpatients, suggesting that PE may be under-diagnosed.
© 2012 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Year:  2012        PMID: 22417249      PMCID: PMC3343190          DOI: 10.1111/j.1538-7836.2012.04697.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  27 in total

1.  Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Low-intensity oral anticoagulation in sickle-cell disease reverses the prethrombotic state: promises for treatment?

Authors:  H J Wolters; H ten Cate; L L Thomas; D P Brandjes; A van der Ende; Y van der Heiden; L W Statius van Eps
Journal:  Br J Haematol       Date:  1995-07       Impact factor: 6.998

3.  Pulmonary changes in sickle cell disease.

Authors:  E H Oppenheimer; J R Esterly
Journal:  Am Rev Respir Dis       Date:  1971-06

4.  Massive pulmonary infarction in sickle cell anemia.

Authors:  J C Maggi; E Nussbaum
Journal:  Pediatr Emerg Care       Date:  1987-03       Impact factor: 1.454

5.  Sickle cell states and cardiomyopathy. Sudden death due to pulmonary thrombosis and infarction.

Authors:  S Rubler; R A Fleischer
Journal:  Am J Cardiol       Date:  1967-06       Impact factor: 2.778

6.  Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group.

Authors:  E P Vichinsky; L D Neumayr; A N Earles; R Williams; E T Lennette; D Dean; B Nickerson; E Orringer; V McKie; R Bellevue; C Daeschner; E A Manci
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

7.  The diagnosis of pulmonary thromboembolism in sickle cell disease.

Authors:  B K Walker; S K Ballas; E R Burka
Journal:  Am J Hematol       Date:  1979       Impact factor: 10.047

8.  Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988.

Authors:  B Lindblad; A Eriksson; D Bergqvist
Journal:  Br J Surg       Date:  1991-07       Impact factor: 6.939

9.  Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises.

Authors:  H Chaplin; M C Monroe; A C Malecek; L K Morgan; J Michael; W A Murphy
Journal:  East Afr Med J       Date:  1989-09

10.  Causes of death in sickle cell disease: an autopsy study.

Authors:  Elizabeth A Manci; Donald E Culberson; Yih-Ming Yang; Todd M Gardner; Randall Powell; Johnson Haynes; Arvind K Shah; Vipul N Mankad
Journal:  Br J Haematol       Date:  2003-10       Impact factor: 6.998

View more
  38 in total

1.  Abnormal Ventilation-Perfusion Scan Is Associated with Pulmonary Hypertension in Sickle Cell Adults.

Authors:  Alem Mehari; Norris Igbineweka; Darlene Allen; Jim Nichols; Swee Lay Thein; Nargues A Weir
Journal:  J Nucl Med       Date:  2018-06-07       Impact factor: 10.057

Review 2.  Fibrinogen and red blood cells in venous thrombosis.

Authors:  Maria M Aleman; Bethany L Walton; James R Byrnes; Alisa S Wolberg
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

Review 3.  Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know.

Authors:  Rakhi P Naik; Michael B Streiff; Sophie Lanzkron
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

Review 4.  Measuring success: utility of biomarkers in sickle cell disease clinical trials and care.

Authors:  Ram Kalpatthi; Enrico M Novelli
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

5.  Pulmonary CTA in sickle cell patients: quantitative assessment of enhancement quality.

Authors:  Jeff Jensen; Tony Lin; Elliot K Fishman; Pamela T Johnson
Journal:  Emerg Radiol       Date:  2017-08-11

Review 6.  Negative health implications of sickle cell trait in high income countries: from the football field to the laboratory.

Authors:  Nigel S Key; Philippe Connes; Vimal K Derebail
Journal:  Br J Haematol       Date:  2015-03-07       Impact factor: 6.998

Review 7.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

8.  Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study.

Authors:  Megan Z Roberts; G Eric Gaskill; Julie Kanter-Washko; T Rogers Kyle; Brittany C Jones; Nicole M Bohm
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

9.  Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication.

Authors:  Rakhi P Naik; Michael B Streiff; Carlton Haywood; Julie A Nelson; Sophie Lanzkron
Journal:  Am J Med       Date:  2013-05       Impact factor: 4.965

10.  Evaluating the safety and effectiveness of venous thromboembolism prophylaxis in patients with sickle cell disease.

Authors:  Denise Kelley; Lauren Thornton Jones; Jun Wu; Nicole Bohm
Journal:  J Thromb Thrombolysis       Date:  2017-05       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.